Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape

Dec 17, 2025The Australian and New Zealand journal of psychiatry

Challenges with using psilocybin in Australian medical treatment: rules, ethics, and practical issues

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Australia's reclassification of psilocybin as a Schedule 8 substance may improve treatment options for depression.

This change positions Australia as a leader in psychedelic medicine.
Challenges include limited prescriber access and high costs.
There is no Australian Register of Therapeutic Goods-listed psilocybin products.
Ethical issues involve informed consent and cultural safety, especially in trauma contexts.
Recommendations include national training accreditation and monitoring tools for therapy.
Research could explore neurobiologically informed models for better treatment recommendations.

AI simplified

Australia's reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatric policy. While this regulatory change positions Australia as a global leader in psychedelic medicine, its implementation has revealed substantial challenges. This article critically examines the regulatory, ethical and operational complexities surrounding the provision of psilocybin-assisted therapy in clinical practice. Key issues include limited prescriber access, absence of Australian Register of Therapeutic Goods-listed products, lack of standardised training pathways and significant cost barriers. Ethical considerations such as informed consent, cultural safety and therapeutic fidelity are also discussed, particularly in the context of trauma-informed care. This article proposes a series of structural recommendations to support safe and equitable deployment, including national training accreditation and fidelity monitoring tools. In addition, to maximise the efficacy of psilocybin-assisted therapy, we recommend that research explores the potential of neurobiologically informed stratification models to assist with treatment recommendations. These recommendations aim to enhance clinical integrity through evidence-based patient selection, improved safety, and to ensure that emerging psychedelic treatments are integrated responsibly within Australia's mental health system. By addressing these foundational gaps, Australia can move beyond regulatory novelty ensuring the therapeutic potential of these products is realised in a manner which is scientifically sound and upholds the integrity of psychiatric practice.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief